The Phase 4 NEW DAY study demonstrates that fluocinolone acetonide (FAc) 0.19 mg implant as baseline therapy achieves similar visual acuity and anatomical improvements compared to aflibercept in diabetic macular edema patients, while significantly reducing total injection burden despite not meeting the primary rescue injection endpoint.